Piper Sandler Maintains Overweight on Moderna, Raises Price Target to $77

Benzinga Newsdesk www.benzinga.com Positive 76.3%

Neg 0% Neu 0% Pos 76.3%

Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $69 to $77.